First-in-class dual HIF inhibitors eliminate tumors in mice when combined with immunotherapy

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression.